Ashley Birkett | Global Head, Malaria Vaccines and Biologics
PATH

Ashley Birkett is the Global Head of Malaria within PATH’s Center for Vaccine Innovation and Access (CVIA) and serves on the CVIA Leadership Team. CVIA brings together expertise across every stage of vaccine research, development, and introduction to make vaccines globally available to women, children, and communities, particularly in low resource settings. He oversees the development and implementation of the malaria program’s strategy, including programmatic, administrative, and financial management aspects, to develop new models and explore new pathways to accelerate the development and introduction of malaria biologics. CVIA’s malaria portfolio encompasses partnered vaccines and monoclonal antibodies at various stages of development, from preclinical through introduction, and is supported by donors in the US, Europe and Asia. He has 25 years of development experience, initially with biotechnology companies, where he successfully advanced novel influenza and malaria vaccine candidates from research through first-in-human clinical studies. Ashley earned a PhD in biochemistry and molecular biophysics from Virginia Commonwealth University.